{"100-1.\n56\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u816b\u7624\u75c5\u53f2\uff0c2\u500b\u6708\u524d\u8d77\u6709\u6f38\u9032\u7684\u982d\u75db\u8207\u6b65\u5c65\u4e0d\u7a69\uff0c\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5\u986f\u793a\u6709\u591a\u9846\u8166\u90e8\u816b\u7624\uff0c\u6700\u6709\u53ef\u80fd\u662f\u7531\u4f55\u8655\u8f49\u79fb\u7684\u816b\u7624\uff1f\nA. \u809d\u81df\uff08liver\uff09\nB. \u4e73\u623f\uff08breast\uff09\nC. \u80ba\u81df\uff08lung\uff09\nD. \u5927\u8178\uff08colon\uff09\nE. \u76ae\u819a\uff08skin\uff09\n": "(C)", "100-2.\n76\u6b72\u7537\u6027\uff0c\u9ad8\u8840\u58d3\u8207\u7cd6\u5c3f\u75c5\u7684\u75c5\u53f2\uff0c\u670d\u7528Amlodipine\u3001Enalapril\u3001Furosemide\u3001Glipizide\u3001Metformin\uff0c\u56e0\u7a81\u767c\u6025\u6027\u8166\u6897\u585e\u4e2d\u98a8\uff0c\u63a5\u53d7\u975c\u8108\u8840\u6813\u6eb6\u89e3\u6cbb\u7642\uff0c\u5728\u6cbb\u7642\u5f8c1\u500b\u5c0f\u6642\u767c\u751f\u820c\u982d\u816b\u8139\u3001\u547c\u5438\u56f0\u96e3\uff0c\u9700\u63d2\u7ba1\u6cbb\u7642\uff0c\u5148\u524d\u6240\u4f7f\u7528\u7684\u4f55\u7a2e\u85e5\u7269\u53ef\u80fd\u8207\u6b64\u526f\u4f5c\u7528\u767c\u751f\u76f8\u95dc\uff1f\nA. Amlodipine\nB. Enalapril\nC. Furosemide\nD. Glipizide\nE. Metformin\n": "(B)", "100-3.\n28\u6b72\u7537\u6027\uff0c\u570b\u5c0f\u6642\u56db\u80a2\u7684\u808c\u529b\u5c31\u8f03\u5dee\uff0c\u570b\u4e2d\u6642\u8e72\u4e0b\u53bb\u7121\u6cd5\u7acb\u5373\u7ad9\u8d77\uff0c\u5408\u4f75\u6709\u5fc3\u5f8b\u4e0d\u6574\uff0c\u8840\u6db2Creatine kinase\u70ba\u6b63\u5e38\u503c5\u500d\uff0c\u5176\u7236\u572840\u6b72\u6642\u56e0\u7a81\u767c\u5fc3\u7387\u4e0d\u6574\u800c\u904e\u4e16\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Limb girdle muscular dystrophy\nB. Myotonic dystrophy\nC. Mitochondrial myopathy\nD. Emery-Dreifuss muscle dystrophy\nE. Becker muscle dystrophy\n": "(D)", "100-4.\n75\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u8207\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c2\u5e74\u524d\u767c\u751f\u53f3\u6795\u8449\u90e8\u8166\u6897\u585e\u5f8c\u958b\u59cb\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u85e5Warfarin\uff0c\u6b64\u6b21\u56e0\u5de6\u5927\u8166\u6897\u585e\u4e2d\u98a8\u5165\u9662\uff0cINR\u70ba1.3\uff0c\u61c9\u8003\u616e\u5982\u4f55\u8abf\u6574\u85e5\u7269\u4ee5\u9810\u9632\u4e2d\u98a8\u518d\u767c\u751f\uff1f\nA. Warfarin \u8207 Aspirin \u4f75\u7528\nB. Warfarin \u8207 Clopidogrel \u4f75\u7528\nC. \u6539\u7528 Aspirin \u8207 Clopidogrel \u4f75\u7528\nD. Warfarin \u8207 Aspirin \u53ca Clopidogrel \u4f75\u7528\nE. \u8abf\u6574 Warfarin \u4f7f\u7528\u5291\u91cf\n": "(E)", "100-5.\n\u6bd4\u8f03\u591a\u767c\u6027\u808c\u708e\uff08polymyositis\uff09\u8207\u76ae\u808c\u708e\uff08dermatomyositis\uff09\uff0c\u4e0b\u5217\u90a3\u4e9b\u72c0\u6cc1\u70ba\u591a\u767c\u6027\u808c\u708e\u8f03\u76ae\u808c\u708e\u5e38\u898b\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\r2.\u764c\u75c7\r3.\u85e5\u7269\u76f8\u95dc\r4.\u7cfb\u7d71\u786c\u5316\u75c7\uff08systemic sclerosis\uff09\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(A)", "100-6.\n50\u6b72\u7537\u6027\uff0c\u6574\u810a\u5f8c\u4e0d\u9069\u81f3\u6025\u8a3a\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u6709\u53f3\u5074\u5ef6\u8166\u5167\u5074\u6897\u585e\uff08right medial medulla infarct\uff09\uff0c\u53ef\u80fd\u6709\u90a3\u4e9b\u75c7\u72c0\u8868\u73fe\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u53f3\u5074\u81c9\u9ebb\r2.\u5de6\u5074\u80a2\u9ad4\u7121\u529b\r3.\u53f3\u5074\u80a2\u9ad4\u5931\u8abf\uff08dysmetria\uff09\r4.\u53f3\u5074\u820c\u982d\u7121\u529b\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(B)", "100-7.\n\u4e0b\u5217\u90a3\u4e9b\u662f\u4ee5\u75bc\u75db\u8868\u73fe\u70ba\u4e3b\u7684\u5468\u908a\u795e\u7d93\u75be\u75c5\uff08painful neuropathy\uff09\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.amyloidosis \uff08\u985e\u6fb1\u7c89\u75c7\uff09\r2.\u7dad\u4ed6\u547dB12\u795e\u7d93\u75c5\u8b8a\uff08vitamin B12 neuropathy\uff09\r3.\u925b\u4e2d\u6bd2\u795e\u7d93\u75c5\u8b8a\uff08lead neuropathy\uff09\r4.\u6cd5\u5e03\u6c0f\u75c7\uff08Fabry's disease\uff09\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(C)", "101-1.\n35\u6b72\u5973\u6027\uff0c\u56e0\u80a9\u9838\u9178\u75db\u63a5\u53d7\u6574\u810a\u63a8\u62ff\uff0c\u9694\u65e5\u767c\u751f\u53f3\u9838\u8207\u982d\u90e8\u75bc\u75db\u3001\u6688\u7729\u3001\u5614\u5410\u3001\u7121\u6cd5\u7ad9\u7acb\u75c7\u72c0\uff0c\u6b64\u60a3\u8005\u53ef\u80fd\u5408\u4f75\u4e0b\u5217\u75c7\u72c0\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u53f3\u81c9\u9ebb\u6728\uff08paresthesia\uff09\nB. \u53f3\u5074\u80a2\u9ad4\u7121\u529b\uff08hemiparesis\uff09\nC. \u53f3\u5074\u80a2\u9ad4\u5931\u8abf\uff08dysmetria\uff09\nD. \u5de6\u5074\u80a2\u9ad4\u9ebb\u6728\uff08hemiparesthesia\uff09\nE. \u53f3\u5074\u773c\u77bc\u4e0b\u5782\uff08ptosis\uff09\n": "(B)", "101-2.\n80\u6b72\u7537\u6027\uff0c\u8fd1\u534a\u5e74\u6709\u8a18\u61b6\u6e1b\u9000\uff0c\u8fd11\u500b\u6708\u5168\u8eab\u7121\u529b\u3001\u5026\u6020\u6b65\u614b\u4e0d\u7a69\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b\u5747\u4e0b\u964d\u3001\u80a2\u9ad4\u9060\u7aef\u66f4\u660e\u986f\u3001\u808c\u9375\u53cd\u5c04\u4e0b\u964d\u4e14\u8b8a\u6162\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u7dad\u4ed6\u547dB1\u7f3a\u4e4f\nB. \u7dad\u4ed6\u547dB12\u7f3a\u4e4f\nC. \u7532\u72c0\u817a\u4f4e\u4e0b\u75c7\uff08hypothyroidism\uff09\nD. \u5e38\u58d3\u6c34\u8166\u75c7\uff08normal pressure hydrocephalus\uff09\nE. \u4f4e\u8840\u9240\u75c7\uff08hypokalemia\uff09\n": "(C)", "101-3.\n70\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8fd11\u9031\u6709\u6578\u6b21\u77ed\u66ab\u9663\u767c\u6027\u53f3\u4e0b\u80a2\u986b\u52d5\uff08limb shaking\uff09\uff0c\u6bcf\u6b21\u6301\u7e8c2\u5206\u9418\uff0c\u591a\u767c\u751f\u5728\u8981\u8d77\u8eab\u884c\u8d70\u6642\uff0c\u767c\u751f\u6642\u610f\u8b58\u6e05\u695a\uff0c\u5408\u4f75\u6709\u51a0\u5fc3\u75c7\u3001\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u8102\u7b49\u3002\u5247\u61c9\u512a\u5148\u5b89\u6392\u4f55\u6aa2\u67e5\uff1f\nA. \u8166\u96fb\u5716\nB. \u80a2\u9ad4\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\nC. \u9838\u810a\u9ad3\u78c1\u632f\u7167\u5f71\u6aa2\u67e5\nD. \u9838\u52d5\u8108\u8d85\u97f3\u6ce2\u8207\u9871\u5167\u8d85\u97f3\u6ce2\nE. \u808c\u96fb\u5716\n": "(D)", "101-4.\n25\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8fd15\u65e5\u6709\u660e\u986f\u53f3\u8033\u75bc\u75db\u50b3\u5230\u4e0b\u984e\u8655\uff0c\u8fd13\u65e5\u6709\u53f3\u81c9\u7121\u529b\u3001\u8033\u9cf4\u8207\u53f3\u8033\u807d\u529b\u4e0b\u964d\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Sarcoidosis\nB. Miller-Fisher syndrome\nC. Tolosa-Hunt syndrome\nD. Ramsay-Hunt syndrome\nE. Leprosy\n": "(D)", "101-5.\n\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u85e5\u7269tissue plasminogen activator\uff0c\u7d041%\u6703\u767c\u751forolingual angioedema\uff08\u820c\u54bd\u8840\u7ba1\u6027\u6c34\u816b\uff09\uff0c\u4f75\u7528\u90a3\u4e00\u985e\u964d\u8840\u58d3\u85e5\u7269\u6700\u53ef\u80fd\u767c\u751f\u6b64\u526f\u4f5c\u7528\uff1f\nA. Beta-blocker\nB. Calcium channel blocker\nC. Alpha-blocker\nD. Diuretics\nE. Angiotensin receptor blocker\n": "(E)", "101-6.\n55\u6b72\u7537\u6027\u56e0\u8b6b\u5984\u5c31\u91ab\uff0c\u6709\u9157\u9152\u53f2\uff0c\u88dc\u5145\u7dad\u4ed6\u547dB1\u8207\u8f38\u6db2\uff0c\u8840\u9209\u8207\u9240\u504f\u4f4e\u7d66\u4e88\u6cbb\u7642\uff0c12\u5c0f\u6642\u5f8c\u767c\u73fe\u56db\u80a2\u660e\u986f\u7121\u529b\u3001\u610f\u8b58\u4e0d\u6e05\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6025\u6027\u7030\u6f2b\u6027\u8166\u810a\u9ad3\u708e\uff08acute disseminated encephalomyelitis\uff09\nB. \u4e2d\u592e\u6a4b\u8166\u812b\u9ad3\u9798\u75c5\u8b8a\uff08central pontine myelinolysis\uff09\nC. Marchiafava-Bignami\u6c0f\u75c5 \uff08Marchiafava-Bignami disease\uff09\nD. \u7dad\u5c3c\u514b\u8166\u75c7\uff08Wernicke's encephalopathy\uff09\nE. \u9ad8\u8840\u9240\u75c7\uff08Hyperkalemia\uff09\n": "(B)", "101-7.\n60\u6b72\u7537\u6027\uff0c\u6709\u9157\u9152\u7fd2\u6163\uff0c\u8fd13\u500b\u6708\u8a18\u61b6\u660e\u986f\u6e1b\u9000\u3001\u6b65\u5c65\u4e0d\u7a69\u73fe\u8c61\uff0c\u56e0\u9aa8\u6298\u63a5\u53d7\u624b\u8853\u5f8c\u767c\u751f\u610f\u8b58\u4e0d\u6e05\u3002\u5247\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u4e0d\u61c9\u7acb\u5373\u9032\u884c\uff1f\r(1) \u7d66\u4e88\u8461\u8404\u7cd6\u9ede\u6ef4\r(2) \u7d66\u4e88Thiamine\r(3) \u9032\u884c\u8170\u690e\u7a7f\u523a\u7684\u810a\u9ad3\u6db2\u6aa2\u67e5\r(4) \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "102-1.\n65\u6b72\u5973\u6027\uff0c\u56e0\u5fc3\u623f\u986b\u52d5\u767c\u751f\u8166\u6897\u585e\u4e2d\u98a8\uff0c\u4e26\u6709\u7672\u7647\u3001\u9ad8\u5c3f\u9178\u3001\u80ba\u7d50\u6838\uff0c\u5728\u4f7f\u7528\u6297\u51dd\u5291warfarin\uff0c\u5408\u4f75\u4f7f\u7528\u5176\u5b83\u90a3\u4e9b\u85e5\u7269\u53ef\u80fd\u6703\u660e\u986f\u589e\u52a0\u8840\u4e2d\u7684INR\uff08international normalized ratio\uff09\u503c\uff1f(1) carbamazepine (2) valproic acid (3) rifampin (4) allopurinol  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "102-2.\n70\u6b72\u7537\u6027\uff0c\u56e0\u80a2\u9ad4\u5bb9\u6613\u767c\u751f\u75d9\u6523\uff08Tetany\uff09\u800c\u5c31\u8a3a\uff0c\u6aa2\u67e5\u6642\u53ef\u80fd\u6703\u767c\u73fe\u90a3\u4e9b\u5fb5\u5019\uff1f(1) Hoffmann sign (2)Trousseau's sign (3)Chvostek's sign (4)Myotonia  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(D)", "102-3.\n65\u6b72\u5973\u6027\u56e0\u5b50\u5bae\u624b\u8853\u5f8c\u81f4\u56b4\u91cd\u8178\u5b50\u4e0d\u8815\u52d5\uff08ileus\uff09\uff0c\u7121\u6cd5\u9032\u98df\u53ea\u80fd\u63a5\u53d7\u975c\u8108\u8f38\u6db2\u88dc\u5145\uff0c\u8fd1\u4e00\u9031\u6709\u6b65\u5c65\u4e0d\u7a69\uff08ataxia\uff09\u3001\u8907\u8996\uff08diplopia\uff09\u3001\u6f38\u6f38\u610f\u8b58\u4e0d\u6e05\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u773c\u632f\uff08nystagmus\uff09\u3001\u773c\u7403\u904b\u52d5\u969c\u7919\u8207\u80a2\u9ad4\u5931\u8abf\uff0c\u53ef\u80fd\u662f\u4f55\u7a2e\u7f3a\u4e4f\u6240\u81f4\uff1f\nA. Thiamine\nB. Pyridoxine\nC. Cobalamin\nD. Riboflavin\nE. Vitamin E\n": "(A)", "102-4.\n65\u6b72\u7537\u6027\uff0c\u982d\u75db\u3001\u5026\u6020\uff0c\u7a81\u767c\u5de6\u5074\u8996\u529b\u55aa\u5931\uff0c\u6aa2\u67e5\u986f\u793a\u70ba\u8996\u795e\u7d93\u708e\uff0c\u4e0b\u5217\u4f55\u8a3a\u65b7\u53ef\u80fd\u6027\u8f03\u9ad8\uff1f\nA. Cerebral sinus thrombosis\nB. Antiphospholipid syndrome\nC. Carotid dissection\nD. Giant cell arteritis\nE. Lyme disease\n": "(D)", "102-5.\n\u95dc\u65bcPOEMS\u75c7\u5019\u7fa4\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u70ba\u6162\u6027\u812b\u9ad3\u9798\u795e\u7d93\u75c5\u8b8a\uff0c\u4f46\u591a\u5c0d\u985e\u56fa\u9187\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\nB. Kappa light chain\u8f03lambda light chain\u5e38\u898b\nC. \u6709\u8996\u4e73\u982d\u6c34\u816b\uff08papilledema\uff09\nD. \u76ae\u819a\u8b8a\u9ed1\u3001\u591a\u6bdb\nE. \u8840\u6e05\u4e2d\u7684\u8840\u7ba1\u5167\u76ae\u751f\u9577\u56e0\u5b50\uff08vascular endothelial growth factor\uff09\u6fc3\u5ea6\u589e\u52a0\n": "(B)", "102-6.\n70\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u7684\u75c5\u53f2\uff0c\u53f3\u6487\uff0c\u5bb6\u4eba\u767c\u73fe\u6700\u8fd1\u4e09\u65e5\u8b8a\u5f97\u4e0d\u6703\u505a\u5bb6\u4e8b\uff0c\u4e5f\u4e0d\u6703\u81ea\u5df1\u7a7f\u8863\u670d\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u8166\u5e79\u529f\u80fd\u6b63\u5e38\u3001\u80a2\u9ad4\u808c\u529b\u6b63\u5e38\u3001\u8a00\u8a9e\u6d41\u66a2\uff0c\u6700\u53ef\u80fd\u7684\u75c5\u8b8a\u4f4d\u7f6e\u5728\u90a3\u88e1\uff1f\nA. \u53f3\u5074\u984d\u8449\uff08frontal lobe\uff09\nB. \u53f3\u5074\u9873\u8449\uff08temporal lobe\uff09\nC. \u53f3\u5074\u9802\u8449\uff08parietal lobe\uff09\nD. \u5de6\u5074\u984d\u8449\uff08frontal lobe\uff09\nE. \u5de6\u5074\u9802\u8449\uff08parietal lobe\uff09\n": "(E)", "102-7.\n\u4e0b\u5217\u4f55\u8005\u975e\u56b4\u91cd\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff08hypothyroidism\uff09\u7684\u795e\u7d93\u5b78\u8868\u73fe\uff1f\nA. \u667a\u80fd\u4f4e\u4e0b\nB. \u808c\u8089\u6523\u7e2e\uff08cramp\uff09\nC. \u808c\u8089\u50f5\u786c\uff08stiffness\uff09\nD. \u808c\u8089\u75bc\u75db\nE. \u808c\u8171\u53cd\u5c04\u589e\u5f37\n": "(E)", "103-1.\n55\u6b72\u7537\u6027\uff0c\u56e0\u5de6\u773c\u816b\u8139\u8207\u9b31\u8840\u5c31\u8a3a\uff0c\u982d\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5de6\u5074\u6d77\u7dbf\u7ac7\uff08cavernous sinus\uff09\u6709\u4e0d\u6b63\u5e38\u986f\u5f71\uff0c\u81e8\u5e8a\u8a3a\u65b7\u70ba\u773c\u7aa9\u9802\u75c7\u5019\u7fa4\uff08orbital apex syndrome\uff09\uff0c\u90a3\u4e00\u689d\u9871\u795e\u7d93\u5b78\u4e0d\u6703\u53d7\u5f71\u97ff\uff1f\nA. \u7b2c\u4e8c\u9871\u795e\u7d93\nB. \u7b2c\u4e09\u9871\u795e\u7d93\nC. \u7b2c\u56db\u9871\u795e\u7d93\nD. \u7b2c\u516d\u9871\u795e\u7d93\nE. \u7b2c\u4e03\u9871\u795e\u7d93\n": "(E)", "103-2.\n25\u6b72\u5973\u6027\uff0c\u56e0\u7a81\u7136\u8907\u8996\u8207\u53f3\u5074\u80a2\u9ad4\u7121\u529b\u5c31\u8a3a\uff0c\u4e4b\u524d\u6709\u5fc3\u96dc\u97f3\u3001\u6700\u8fd13\u500b\u6708\u6709\u8f15\u5ea6\u767c\u71d2\u3001\u5026\u6020\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u6aa2\u67e5\u6642\u9808\u6ce8\u610f\u54ea\u4e9b\u5fb5\u5019\uff1f(1) Gottron's sign (2) Janeway's lesion (3) Heliotrope sign (4) Roth's spot (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "103-3.\n40\u6b72\u5973\u6027\u56e0\u9663\u767c\u6027\u982d\u75db\u5c31\u91ab\uff0c\u982d\u75db\u4f4d\u5728\u5de6\u5074\u9873\u8449\u8207\u773c\u7736\u9644\u8fd1\uff0c\u6bcf\u6b21\u75db10\u81f320\u5206\u9418\uff0c\u6bcf\u5929\u75db8-10\u6b21\uff0c\u8166\u96fb\u5716\u8207\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5\u6b63\u5e38\uff0c\u61c9\u512a\u5148\u9078\u64c7\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\uff1f\nA. Verapamil\nB. Sumatriptan\nC. Topiramide\nD. Indomethacin\nE. Propranolol\n": "(D)", "103-4.\n40\u6b72\u7537\u6027\u525b\u88ab\u8a3a\u65b7\u6709\u7672\u7647\u75be\u75c5\uff0c\u904e\u53bb\u4e26\u7121\u8166\u708e\u3001\u8166\u5916\u50b7\u3001\u6216\u7279\u6b8a\u75c5\u53f2\uff0c\u6700\u6709\u53ef\u80fd\u662f\u4f55\u7a2e\u7672\u7647\u578b\u614b\uff1f\nA. \u5927\u767c\u4f5c\u7672\u7647\uff08Grand mal seizure\uff09\nB. \u5931\u795e\u7672\u7647\uff08Absence seizure\uff09\nC. \u8907\u96dc\u5c40\u90e8\u7672\u7647\uff08Complex partial seizure\uff09\nD. \u808c\u8e8d\u6027\u7672\u7647\uff08Myoclonic seizure\uff09\nE. \u7672\u7647\u5f8c\u7671\u7613\uff08Todd paralysis\uff09\n": "(C)", "103-5.\n70\u6b72\u7537\u6027\u6709\u53f3\u5074\u7684\u6a4b\u8166\u6897\u585e\uff08pons infarction\uff09\uff0c\u7522\u751f1\u53c81/2\u75c7\u5019\u7fa4\uff08One-and-a-half syndrome\uff09\uff0c\u5247\u4e0b\u5217\u773c\u7403\u52d5\u4f5c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u53f3\u773c\u7403\u7121\u6cd5\u5411\u5916\u8f49\u52d5\nB. \u53f3\u773c\u7403\u7121\u6cd5\u5411\u5167\u8f49\u52d5\nC. \u5de6\u773c\u7403\u7121\u6cd5\u5411\u5167\u8f49\u52d5\nD. \u5de6\u773c\u7403\u7121\u6cd5\u5411\u5916\u8f49\u52d5\nE. \u53f3\u773c\u7403\u53ef\u5411\u4e0b\u8f49\u52d5\n": "(D)", "103-6.\n25\u6b72\u7537\u6027\uff0c\u56e0\u56b4\u91cd\u8e81\u52d5\u8207\u80a2\u9ad4\u986b\u52d5\u5c31\u91ab\uff0c\u75c5\u60a3\u6709\u7cbe\u795e\u75be\u75c5\uff0c\u4f7f\u7528lithium\u3001clozapine\u3001valproic acid\u7b49\u85e5\u7269\uff0c\u75c5\u60a3\u610f\u8b58\u6df7\u4e82\uff0c\u9ad4\u6eab39\u2103\uff0c\u8840\u58d3 120/82 mmHg\uff0c\u8108\u640f 105/\u5206\u9418\uff0c\u5168\u8eab\u50f5\u786c\uff08rigidity\uff09\u8207\u986b\u6296\uff08tremor\uff09\uff0c\u808c\u9150\u9178\ufffdC\uff08creatine kinase\uff09\u70ba2450 units/L\uff0c\u6700\u53ef\u80fd\u662f\u54ea\u4e00\u8a3a\u65b7\uff1f\nA. \u92f0\u9e7d\u4e2d\u6bd2\nB. valproic acid\u904e\u91cf\nC. \u8840\u6e05\u7d20\u75c7\u5019\u7fa4\uff08serotonin syndrome\uff09\nD. \u60e1\u6027\u9ad8\u9ad4\u6eab\uff08malignant hyperthermia\uff09\nE. \u6297\u7cbe\u795e\u75c5\u85e5\u7269\u60e1\u6027\u75c7\u5019\u7fa4\uff08neuroleptic malignant syndrome\uff09\n": "(E)", "103-7.\n82\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u56e0\u6025\u6027\u4e2d\u98a8\u5c31\u91ab\uff0c\u8a3a\u65b7\u70ba\u5de6\u5074\u5927\u7bc4\u570d\u4e2d\u5927\u8166\u52d5\u8108\u6897\u585e\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\uff08NIHSS\uff09\u5206\u6578\u70ba18\u5206\uff0c\u8840\u7cd6230 mg/dL\uff0c\u73fe\u70ba\u4e2d\u98a8\u767c\u751f\u5f8c6\u5c0f\u6642\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u9069\u7576\uff1f(1) \u66ab\u6642\u5148\u4e0d\u8981\u7d66\u4e88\u6297\u8840\u6813\u85e5\u7269 (2) \u53ef\u8003\u616e\u4e00\u5468\u5f8c\u958b\u59cb\u4f7f\u7528\u65b0\u578b\u53e3\u670d\u6297\u51dd\u5291 (3) \u82e5\u8840\u58d3\u70ba190/90 mmHg\u4e0d\u8981\u7acb\u5373\u964d\u58d3 (4) \u53ef\u8003\u616e\u7a4d\u6975\u80f0\u5cf6\u7d20\u8f38\u6ce8\uff08insulin infusion\uff09\u4ee5\u56b4\u683c\u63a7\u5236\u8840\u7cd6\u3002(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "104-1.\n20\u6b72\u5973\u6027\u56e0\u5de6\u624b\u7121\u529b\u5c31\u8a3a\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u5de6\u5074\u7684\u624b\u6307\u7121\u6cd5\u5b8c\u5168\u5f35\u958b\u8207\u9589\u5408\uff0c\u638c\u9aa8\u9593\u808c\uff08interossei muscle\uff09\u7121\u529b\u840e\u7e2e\uff0c\u662f\u90a3\u4e00\u689d\u795e\u7d93\u53d7\u640d\uff1f\nA. \u6b63\u4e2d\u795e\u7d93\uff08median nerve\uff09\nB. \u5c3a\u795e\u7d93\uff08ulnar nerve\uff09\nC. \u6a48\u795e\u7d93\uff08radial nerve\uff09\nD. \u808c\u8868\u76ae\u795e\u7d93\uff08musculocutaneous nerve\uff09\nE. \u9577\u80f8\u795e\u7d93\uff08long thoracic nerve\uff09\n": "(B)", "104-2.\n25\u6b72\u5973\u6027\u6709\u7d05\u6591\u6027\u72fc\u7621\uff08systemic lupus erythematosus\uff09\u5408\u4f75\u814e\u708e\u67093\u5e74\uff0c\u4f7f\u7528\u985e\u56fa\u9187\u3001\u514d\u75ab\u6291\u5236\u5291\uff08cyclophosphamide\uff09\uff0c\u56e0\u610f\u8b58\u4e0d\u6e05\u8207\u7672\u7647\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u8840\u58d3200/110 mmHg\u3001\u9ad4\u6eab37\u00b0C\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\u3001\u86cb\u767d\u6fc3\u5ea6\u7a0d\u589e\u52a0\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5169\u5074\u6795\u8449\u6709\u4e0d\u6b63\u5e38\u8a0a\u865f\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u8166\u819c\u8166\u708e\uff08meningoencephalitis\uff09\nB. \u5c3f\u6bd2\u8166\u75c5\u8b8a\uff08uremic encephalopathy\uff09\nC. \u6025\u6027\u53bb\u9ad3\u9798\u8166\u708e\uff08acute demyelinating encephalitis\uff09\nD. \u6025\u6027\u8166\u6897\u585e\uff08acute cerebral infarction\uff09\nE. \u53ef\u9006\u6027\u5f8c\u8166\u75c5\u8b8a\u75c7\u5019\u7fa4\uff08posterior reversible encephalopathy syndrome\uff09\n": "(E)", "104-3.\n25\u6b72\u5973\u6027\uff0c\u56e0\u7a81\u7136\u8907\u8996\u8207\u53f3\u5074\u80a2\u9ad4\u7121\u529b\u5c31\u8a3a\uff0c\u4e4b\u524d\u6709\u5fc3\u96dc\u97f3\u3001\u6700\u8fd13\u500b\u6708\u6709\u8f15\u5ea6\u767c\u71d2\u3001\u5026\u6020\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u6aa2\u67e5\u6642\u9808\u6ce8\u610f\u54ea\u4e9b\u5fb5\u5019\uff1f(1) Gottron's sign\uff1b(2) Janeway's lesion\uff1b(3) Heliotrope sign\uff1b(4) Roth's spot\u3002\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(1)\nE. (2)+(4)\n": "(E)", "104-4.\n55\u6b72\u5973\u6027\u56e0\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u3001\u74e3\u819c\u7f6e\u63db\u8207\u5fc3\u623f\u986b\u52d5\uff0c\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\uff0c\u56e0\u8166\u51fa\u8840\u81f3\u6025\u8a3a\uff0cINR\u70ba5.5\uff0c\u4f7f\u7528\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u80fd\u6700\u5feb\u6062\u5fa9\u51dd\u8840\u529f\u80fd\uff1f\r\n(1) Vitamin K\uff1b(2) Fresh frozen plasma\uff1b(3)Platelets\uff1b(4)Prothrombin complex concentrates\uff1b(5) Whole blood\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (1)+(2)+(4)\nD. (1)+(3)+(5)\nE. (1)+(4)+(5)\n": "(A or B or C or D)", "104-5.\n50\u6b72\u5973\u6027\u7f79\u60a3\u808c\u7121\u529b\uff08myasthenia gravis\uff094\u5e74\uff0c\u56e0\u80ba\u708e\u4f75\u767c\u547c\u5438\u8870\u7aed\u5165\u4f4f\u52a0\u8b77\u75c5\u623f\uff0c\u4e0b\u5217\u90a3\u4e9b\u985e\u5225\u7684\u6297\u751f\u7d20\u8f03\u4e0d\u9069\u5408\u4f7f\u7528\uff1f(1) Quinolones\uff1b(2) Beta-lactam + beta-lactamase inhibitor\uff1b(3) Macrolides\uff1b(4) Cephalosporins\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "104-6.\n\u76f8\u8f03\u65bc\u808c\u7121\u529b\uff08myasthenia gravis\uff09\uff0c\u85cd\u4f2f-\u4f0a\u9813\u808c\u7121\u529b\u75c7\uff08Lambert-Eaton myasthenic syndrome\uff09\u8f03\u5e38\u51fa\u73fe\u90a3\u4e9b\u75c7\u72c0\uff1f(1) \u773c\u76ae\u4e0b\u5782\u3001\u8907\u8996\uff1b(2) \u808c\u8171\u53cd\u5c04\u4e0b\u964d\uff1b(3) \u53e3\u9f52\u4e0d\u6e05\u53ca\u541e\u56a5\u56f0\u96e3\uff1b(4) \u81ea\u5f8b\u795e\u7d93\u5931\u8abf\u75c7\u72c0\uff0c\u5982\u53e3\u4e7e\u3001\u4fbf\u79d8\u3001\u5c0f\u4fbf\u56f0\u96e3\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "104-7.\n40\u6b72\u5973\u59d3\u56e0\u80a2\u9ad4\u986b\u6296\u5c31\u8a3a\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\u986f\u793a\u6709\u660e\u986f\u5169\u5074\u57fa\u5e95\u6838\u9223\u5316\uff0c\u4e0b\u5217\u90a3\u4e9b\u75be\u75c5\u9808\u8003\u616e\uff1f(1) \u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\uff08carbon monoxide intoxication\uff09\uff1b(2) \u7c92\u7dda\u9ad4\u75be\u75c5\uff08mitochondrial disease\uff09\uff1b(3) \u8166\u56ca\u5c3e\u5e7c\u87f2\u75c7\uff08neurocysticercosis\uff09\uff1b(4) \u526f\u7532\u72c0\u817a\u4f4e\u80fd\u75c7\uff08hypoparathyroidism\uff09\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(E)", "105-1.\n60\u6b72\u7537\u6027\u56e0\u4e3b\u52d5\u8108\u525d\u96e2\u4f4f\u9662\uff0c\u4f4f\u9662\u4e2d\u767c\u751f\u56db\u80a2\u7121\u529b\u8207\u5931\u7981\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b\u70ba1\u5206\uff0c\u56db\u80a2\u808c\u8171\u53cd\u5c04\u589e\u52a0\uff0c\u8e60\u53cd\u5c04\uff08plantar reflex\uff09\u70ba\u5411\u4e0a\uff0c\u91dd\u523a\u611f\u89ba\uff08pin prick sense\uff09\u81ea\u80f8\u90e8\u4ee5\u4e0b\u55aa\u5931\uff0c\u95dc\u7bc0\u6d3b\u52d5\u611f\u89ba\uff08joint position sense\uff09\u5247\u6b63\u5e38\uff0c\u4f55\u7a2e\u75c5\u8b8a\u7684\u53ef\u80fd\u6027\u6700\u9ad8\uff1f\nA. \u786c\u8166\u819c\u5916\u81bf\u760d\uff08epidural abscess\uff09\nB. \u786c\u8166\u819c\u4e0b\u8840\u816b\uff08subdural hematoma\uff09\nC. \u524d\u810a\u690e\u52d5\u8108\u75c7\u5019\u7fa4\uff08anterior spinal artery syndrome\uff09\nD. \u6025\u6027\u6a6b\u8cab\u6027\u810a\u9ad3\u708e\uff08acute transverse myelitis\uff09\nE. \u786c\u8166\u819c\u5916\u8840\u816b\uff08epidural hematoma\uff09\n": "(C)", "105-2.\n20\u6b72\u7537\u6027\uff0c\u56e0\u7761\u7720\u554f\u984c\u770b\u8a3a\uff0c\u4e3b\u8a34\u6709\u4e0b\u5217\u75c7\u72c0\uff0c\u4f55\u8005\u662f\u8a3a\u65b7\u731d\u7761\u75c7\uff08narcolepsy\uff09\u6700\u660e\u78ba\uff08specific\uff09\u7684\u75c7\u72c0\uff1f\nA. \u767d\u5929\u4e0a\u8ab2\u6642\u5f88\u5bb9\u6613\u7761\u8457\nB. \u5927\u7b11\u6642\u6703\u5168\u8eab\u7121\u529b\nC. \u5e38\u4e00\u8eba\u4e0b\u5c31\u7761\u8457\u4e86\nD. \u767d\u5929\u7cbe\u795e\u5e38\u4e0d\u4f73\nE. \u525b\u7761\u9192\u6642\u6709\u5e7b\u89ba\n": "(B)", "105-3.\n40\u6b72\u5973\u6027\u56e0\u5927\u91cf\u6d41\u6c57\u3001\u767c\u71d2\u3001\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u6aa2\u67e5\u986f\u793a\u8108\u640f\u6bcf\u5206\u9418120\u4e0b\u3001\u80a2\u9ad4\u50f5\u76f4(rigidity)\u3001\u808c\u8171\u53cd\u5c04\u589e\u52a0 (hyperreflexia)\u3002\u75c5\u4eba\u6709\u6182\u9b31\u75c7\u75c5\u53f2\uff0c\u5728\u7cbe\u795e\u79d1\u9580\u8a3a\u770b\u8a3a\u7528\u85e5\uff0c\u6700\u6709\u53ef\u80fd\u662f\u4e0b\u5217\u4f55\u8a3a\u65b7\uff1f\nA. \u97cb\u5c3c\u514b\u6c0f\u8166\u75c5\uff08Wernicke's encephalopathy\uff09\nB. \u75c5\u6bd2\u8166\u708e\uff08viral encephalitis\uff09\nC. \u6297\u7cbe\u795e\u85e5\u7269\u60e1\u6027\u75c7\u5019\u7fa4\uff08neuroleptic malignant syndrome\uff09\nD. \u93ae\u975c\u5291\u904e\u91cf\uff08tranquilizer overdose\uff09\nE. \u8840\u6e05\u75c7\u5019\u7fa4\uff08serotonin syndrome\uff09\n": "(E)", "105-4.\n30\u6b72\u5973\u6027\u56e0\u96d9\u4e0b\u80a2\u7121\u529b\u3001\u9ebb\u6728\u8207\u5931\u7981\u5c31\u91ab\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\uff0c\u8461\u8404\u7cd6\u70ba70 mg/dL\u3001\u5168\u90e8\u86cb\u767d\u70ba75 mg/dL\u3001\u767d\u86cb\u767d\u70ba50 mg/dL\u3001IgG\u70ba20 mg/dL\uff0c\u8840\u6e05\u7684\u767d\u86cb\u767d\u70ba3000 mg/dL\u3001IgG\u70ba1000 mg/dL\uff0c\u5247\u5979\u7684IgG index\u662f\u591a\u5c11\uff1f\nA. \u22671.20\nB. 1.00~1.19\nC. 0.80~0.99\nD. 0.60~0.79\nE. <0.60\n": "(A)", "105-5.\n55\u6b72\u7537\u6027\uff0c\u9577\u671f\u65bc\u67d0\u4e00\u5de5\u5ee0\u5de5\u4f5c\uff0c\u8fd16\u500b\u6708\u6709\u6f38\u9032\u7684\u6b65\u5c65\u8b8a\u5c0f\u3001\u52d5\u4f5c\u8b8a\u6162\u3001\u5e73\u8861\u8b8a\u5dee\uff0c\u8a3a\u65b7\u70ba\u5df4\u91d1\u68ee\u6c0f\u75c7\uff08parkinsonism\uff09\uff0c\u67092\u4f4d\u5de5\u5ee0\u540c\u4e8b\u6709\u985e\u4f3c\u4f46\u8f03\u8f15\u7684\u75c7\u72c0\uff0c\u6700\u9700\u8981\u61f7\u7591\u70ba\u4f55\u7a2e\u4e2d\u6bd2\uff1f\nA. \u925b\uff08lead\uff09\nB. \u9333\uff08manganese\uff09\nC. \u6c5e\uff08mercury\uff09\nD. \u7837\uff08arsenic\uff09\nE. \u9285\uff08copper\uff09\n": "(B)", "105-6.\n\u6162\u6027\u814e\u81df\u75be\u75c5\uff08chronic kidney disease\uff09\u75c5\u4eba\u63a5\u53d7\u900f\u6790\u6cbb\u7642\u7684\u6642\u5019\uff0c\u767c\u751f\u900f\u6790\u5931\u8861\u75c7\u5019\u7fa4\uff08dialysis disequilibrium syndrome\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u5728\u900f\u6790\u7d50\u675f\u6642\u767c\u751f\uff0c\u800c\u975e\u900f\u6790\u958b\u59cb\u524d\u767c\u751f\nB. \u6703\u8868\u73fe\u7a81\u773c\u3001\u773c\u58d3\u9ad8\nC. \u6703\u8868\u73fe\u982d\u75db\u3001\u7672\u7647\nD. \u56e0\u6c34\u5206\u81ea\u8166\u90e8\u812b\u51fa\u592a\u591a\u6240\u81f4\nE. \u56e0\u79fb\u9664\u5c3f\u7d20\u592a\u5feb\u6240\u81f4\n": "(D)", "105-7.\n25\u6b72\u7537\u60271\u5e74\u524d\u66fe\u767c\u751f\u8eca\u798d\u81f4\u9396\u9aa8\u9aa8\u6298\uff0c\u534a\u5e74\u524d\u8d77\u6f38\u9032\u53f3\u4e0a\u80a2\u7121\u529b\u3001\u9ebb\u6728\u8207\u51b0\u51b7\u5c31\u8a3a\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u53f3\u4e0a\u80a2\u5167\u5074\u611f\u89ba\u9072\u920d\u3001\u53f3\u624b\u808c\u529b\u8f03\u5dee\uff0c\u53f3\u81c2\u8840\u58d3\u70ba90/60 mmHg\u3001\u5de6\u81c2\u8840\u58d3\u70ba130/80 mmHg\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u9838\u795e\u7d93\u6839\u75c5\u8b8a\uff08cervical radiculopathy\uff09\nB. \u80f8\u5ed3\u51fa\u53e3\u75c7\u5019\u7fa4\uff08thoracic outlet syndrome)\nC. \u81c2\u795e\u7d93\u53e2\u75c5\u8b8a\uff08brachial plexopathy\uff09\nD. \u8155\u96a7\u9053\u75c7\u5019\u7fa4\uff08carpal tunnel syndrome\uff09\nE. \u9396\u9aa8\u4e0b\u52d5\u8108\u7aca\u8840\u75c7\u5019\u7fa4\uff08subclavian steal syndrome\uff09\n": "(B)", "106-1.\n75\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u3001\u51a0\u5fc3\u75c7\uff0c\u67d0\u65e5\u7a81\u7136\u767c\u73fe\u5de6\u773c\u5e7e\u4e4e\u770b\u4e0d\u898b\uff0c\u75c7\u72c0\u6301\u7e8c\u7d0410\u5206\u9418\u5f8c\u8996\u529b\u9010\u6f38\u6062\u5fa9\uff0c\u61c9\u512a\u5148\u5b89\u6392\u90a3\u4e00\u500b\u6aa2\u67e5\uff1f\nA. \u7d93\u80f8\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nB. \u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nC. \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nD. \u9838\u52d5\u8108\u8d85\u97f3\u6ce2\u6aa2\u67e5\nE. \u8996\u91ce\u6aa2\u67e5\n": "(D)", "106-2.\n50\u6b72\u5973\u6027\uff0c\u6bcf\u665a\u525b\u7761\u6642\u6703\u6709\u4e0b\u80a2\u5f88\u4e0d\u8212\u670d\u611f\u89ba\uff0c\u5fc5\u9808\u8981\u52d5\u4e00\u52d5\u8173\u624d\u6703\u8212\u670d\u4e9b\uff0c\u7761\u89ba\u6642\u88ab\u767c\u73fe\u6703\u9663\u767c\u6027\u7684\u77ed\u66ab\u8173\u6296\u52d5\uff0c\u82e5\u9700\u4f7f\u7528\u85e5\u7269\u53ef\u512a\u5148\u8003\u616e\u54ea\u4e00\u985e\u85e5\u6cbb\u7642\uff1f\nA. Dopamine agonist\nB. Dopamine antagonist\nC. Serotonin antagonist\nD. Selective serotonin-reuptake inhibitor (SSRI)\nE. Monoamine oxidase inhibitor (MAOI)\n": "(A)", "106-3.\n40\u6b72\u5973\u6027\uff0c2\u500b\u6708\u524d\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u4f7f\u7528cyclosporine\uff0c\u7a81\u767c\u982d\u75db\u3001\u7672\u7647\u3001\u610f\u8b58\u4e0d\u6e05\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u6aa2\u67e5\u6700\u53ef\u80fd\u767c\u73fe\u75c5\u7076\u4f4d\u7f6e\u70ba\u4f55\uff1f\nA. \u984d\u8449\uff08frontal lobe\uff09\nB. \u6a4b\u8166\uff08pons\uff09\nC. \u9873\u8449\uff08temporal lobe\uff09\nD. \u6795\u8449\uff08occipital lobe\uff09\nE. \u4e2d\u8166\uff08midbrain\uff09\n": "(D)", "106-4.\n\u5c0d\u65bc\u4e2d\u98a8\u7684\u4e8c\u6b21\u9810\u9632\u5371\u96aa\u56e0\u5b50\u7684\u63a7\u5236\uff0c\u4e0b\u5217\u54ea\u4e9b\u6cbb\u7642\u6240\u9700\u8981\u7684\u500b\u6848\u6578\u4ee5\u964d\u4f4e\u4e00\u500b\u4e2d\u98a8\u767c\u751f\uff08Number needed to treat, NNT\uff09\uff0cNNT\u7531\u5c0f\u5230\u5927\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nB. \u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\nC. \u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nD. \u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nE. \u9ad8\u8840\u8102\u964d\u8840\u8102\u3001\u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\n": "(A)", "106-5.\n25\u6b72\u7537\u6027\uff0c\u8fd13\u65e5\u6709\u6f38\u9032\u56db\u80a2\u7121\u529b\u3001\u80a2\u9ad4\u672b\u7aef\u9ebb\u6728\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b3-4\u5206\u3001\u80a2\u9ad4\u9060\u7aef\u8f03\u8fd1\u7aef\u7121\u529b\u3001\u808c\u8171\u53cd\u5c04\u6d88\u5931\uff0c1\u9031\u524d\u6709\u4e0a\u547c\u5438\u9053\u611f\u67d3\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u7d50\u679c\u6700\u53ef\u80fd\u662f\u4e0b\u8ff0\u4f55\u8005\uff1f\nA. \u86cb\u767d40 mg/dL\u3001\u8461\u8404\u7cd675 mg/dL\u3001\u767d\u8840\u74035/\u03bcL\u3001\u521d\u58d3 200 mmH2O\nB. \u86cb\u767d200 mg/dL\u3001\u8461\u8404\u7cd645 mg/dL\u3001\u767d\u8840\u7403100/\u03bcL\u3001\u521d\u58d3 250 mmH2O\nC. \u86cb\u767d150 mg/dL\u3001\u8461\u8404\u7cd685 mg/dL\u3001\u767d\u8840\u74033/\u03bcL\u3001\u521d\u58d3 120 mmH2O\nD. \u86cb\u767d100 mg/dL\u3001\u8461\u8404\u7cd655 mg/dL\u3001\u767d\u8840\u740320/\u03bcL\u3001\u521d\u58d3 180 mmH2O\nE. \u86cb\u767d80 mg/dL\u3001\u8461\u8404\u7cd665 mg/dL\u3001\u767d\u8840\u740310/\u03bcL\u3001\u521d\u58d3 300 mmH2O\n": "(C)", "106-6.\n60\u6b72\u7537\u6027\u56e0\u4e3b\u52d5\u8108\u525d\u96e2\u4f75\u767c\u80f8\u810a\u9ad3\u6897\u585e\uff0c\u4e0b\u80a2\u611f\u89ba\u529f\u80fd\u90a3\u4e9b\u6700\u53ef\u80fd\u53d7\u5230\u5f71\u97ff(1)\u9707\u52d5\u611f(vibration)\uff1b(2)\u6eab\u5ea6\u611f(temperature)\uff1b(3) \u91dd\u523a\u611f(pin-prick)\uff1b(4) \u95dc\u7bc0\u4f4d\u7f6e\u611f(joint position sense)\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(D)", "106-7.\n\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u5c6c\u65bc\u5c0f\u8840\u7ba1\u75c5\u8b8a\uff1f(1)\u6bdb\u6bdb\u6a23\u75c5(Moya-moya disease)\uff1b(2)\u9ad4\u986f\u6027\u8166\u52d5\u8108\u8840\u7ba1\u75c5\u8b8a\u5408\u4f75\u76ae\u8cea\u4e0b\u8166\u6897\u585e\u53ca\u8166\u767d\u8cea\u75c5\u8b8a(Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CADASIL)\uff1b(3)\u9ad8\u5b89\u6c0f\u52d5\u8108\u708e(Takayasu's arteritis)\uff1b(4)\u9ad8\u8840\u58d3\u8166\u51fa\u8840(Hypertensive intracerebral hemorrhage)\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "107-1.\n25\u6b72\u7537\u6027\uff0c\u9a0e\u8173\u8e0f\u8eca\u6642\u767c\u751f\u8eca\u798d\u6454\u5012\uff0c\u7acb\u5373\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u5165\u6025\u8a3a\u6642\uff0c\u610f\u8b58\u6e05\u695a\uff0c\u8840\u58d3120/70 mmHg\uff0c\u81c9\u8207\u8eab\u9ad4\u6709\u591a\u8655\u64e6\u50b7\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u5927\u8166\u76ae\u8cea\u529f\u80fd\u8207\u9871\u795e\u7d93\u6b63\u5e38\uff0c\u4e0a\u80a2\u808c\u529b5\u5206\uff0c\u96d9\u4e0b\u80a2\u808c\u529b3-4\u5206\uff0c\u4e0b\u80a2\u808c\u9375\u53cd\u5c04\u4e0b\u964d\uff0c\u81ea\u809a\u81cd\u4ee5\u4e0b\u91dd\u523a\u611f\u964d\u4f4e\u3002\u8acb\u554f\u61c9\u7acb\u5373\u9032\u884c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e?\nA. \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nB. \u80f8\u90e8\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nC. \u9ad4\u611f\u8a98\u767c\u96fb\u4f4d\u6aa2\u67e5\nD. \u975c\u8108\u7d66\u4e88\u9ad8\u5291\u91cfmethylprednisolone\nE. \u975c\u8108\u7d66\u4e88\u6297\u7672\u7647\u85e5\u7269\uff08\u5982\uff1alevetiracetam\uff09\n": "(D)", "107-2.\n75\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u5e73\u6642\u672a\u898f\u5247\u7528\u85e5\uff0c\u7a81\u767c\u53f3\u5074\u7121\u529b\u8207\u5931\u8a9e\uff0c\u96a8\u5373\u88ab\u9001\u81f3\u6025\u8a3a\u8655\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\u7684\u5206\u6578\u70ba18\u5206\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u986f\u793a\u7121\u8166\u5167\u51fa\u8840\uff0c\u81ea\u75c7\u72c0\u767c\u751f\u5df2\u7d93120\u5206\u9418\uff0c\u61c9\u9032\u884c\u4e0b\u5217\u4f55\u8655\u7f6e\u8f03\u9069\u5b9c?\nA. \u7acb\u5373\u7d66\u4e88aspirin 300\u6beb\u514b\nB. \u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\uff0c\u65bd\u625360\u5206\u9418\uff0c\u5bc6\u5207\u89c0\u5bdf\u662f\u5426\u6709\u9032\u6b65\nC. \u61f7\u7591\u4e2d\u5927\u8166\u52d5\u8108\u7ba1\u963b\u585e\uff0c\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\nD. \u61f7\u7591\u4e2d\u5927\u8166\u52d5\u8108\u7ba1\u963b\u585e\uff0c\u7acb\u5373\u5165\u5c0e\u7ba1\u5ba4\uff0c\u76f4\u63a5\u505a\u8840\u7ba1\u651d\u5f71\nE. \u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\uff0c\u4e26\u540c\u6642\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\n": "(E)", "107-3.\n\u95dc\u65bc\u8f15\u5ea6\u667a\u80fd\u969c\u7919\uff08mild cognitive impairment, MCI\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u6bcf\u5e74\u670910-15%\u6703\u9000\u5316\u70ba\u5931\u667a\nB. \u8207apolipoprotein E\uff08APOE epsilon 4\uff09\u57fa\u56e0\u578b\u76f8\u95dc\nC. \u660e\u986f\u81ea\u89ba\u6216\u5bb6\u4eba\u767c\u89ba\u5bb9\u6613\u5065\u5fd8\nD. \u793e\u4ea4\u529f\u80fd\u5df2\u660e\u986f\u53d7\u5f71\u97ff\nE. \u8840\u7ba1\u6027\u7684MCI\u5e38\u5408\u4f75\u52d5\u4f5c\u8b8a\u9072\u7de9\n": "(D)", "107-4.\n\u95dc\u65bc\u6025\u6027\u7f3a\u8840\u4e2d\u98a8\u6642\u7684\u8840\u58d3\u8abf\u63a7\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u8f03\u4e0d\u5efa\u8b70\u81e8\u5e8a\u5e38\u898f\u57f7\u884c?\nA. \u975c\u8108\u8840\u6813\u6eb6\u89e3\u524d\uff0c\u8840\u58d3\u8981\u5148\u63a7\u5236\u5728185/110 mmHg\u4ee5\u4e0b\nB. \u975c\u8108\u8840\u6813\u6eb6\u89e3\u5f8c\uff0c\u8840\u58d3\u8981\u5148\u63a7\u5236\u5728180/105 mmHg\u4ee5\u4e0b\nC. \u52d5\u8108\u8840\u6813\u79fb\u9664\u8853\u5f8c\uff0c\u6536\u7e2e\u58d3\u90fd\u61c9\u63a7\u5236\u5728130 mmHg\u4ee5\u4e0b\nD. \u672a\u9032\u884c\u8840\u6813\u6eb6\u89e3\u6216\u8840\u6813\u79fb\u9664\u8853\uff0c\u8840\u58d3\u672a\u8d85\u904e220/120 mmHg\uff0c\u4e0d\u9808\u7acb\u5373\u964d\u8840\u58d3\nE. \u7576\u795e\u7d93\u75c7\u72c0\u7a69\u5b9a\u6642\uff0c\u8840\u58d3\u53ef\u6f38\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\n": "(C)", "107-5.\n60\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u5728\u665a\u4e0a\u770b\u96fb\u8996\u6216\u8eba\u5728\u5e8a\u4e0a\u8981\u5165\u7761\u524d\u5e38\u6703\u611f\u5230\u5169\u817f\u5f88\u4e0d\u8212\u670d\uff0c\u8981\u8d77\u4f86\u52d5\u52d5\u817f\u624d\u6703\u7de9\u89e3\uff0c\u8acb\u554f\u9019\u500b\u75be\u75c5\u53ef\u4f7f\u7528\u7684\u6cbb\u7642\u85e5\u7269\uff0c\u4f55\u8005\u9664\u5916?\nA. \u591a\u5df4\u80fa\u63a5\u53d7\u9ad4\u4fc3\u6548\u5291\uff08\u5982ropinirole\uff09\nB. \u6297\u7672\u7647\u85e5\u7269\uff08\u5982gabapentin\uff09\nC. \u591a\u5df4\u80fa\u4fc3\u9032\u85e5\u7269\uff08\u5982levodopa\uff09\nD. \u6297\u6182\u9b31\u5291\uff08\u5982fluxetine\uff09\nE. \u9435\u5291\u88dc\u5145\n": "(D)", "107-6.\n\u4e0b\u5217\u4f55\u8005\u975e\u7dad\u4ed6\u547dB12\u7f3a\u4e4f\u5c0e\u81f4\u7684\u795e\u7d93\u529f\u80fd\u7570\u5e38\u7684\u5178\u578b\u75c7\u72c0\u8207\u5fb5\u5019?\nA. \u8a18\u61b6\u9000\u5316\nB. \u6b65\u5c65\u4e0d\u7a69\nC. \u80a2\u9ad4\u91dd\u523a\u611f\u4e0b\u964d\nD. \u808c\u8171\u53cd\u5c04\u4e0b\u964d\nE. \u80a2\u9ad4\u9707\u52d5\u611f\u4e0b\u964d\n": "(C)", "107-7.\n55\u6b72\u5973\u6027\uff0c\u7d042-3\u9031\u524d\u6709\u8179\u7009\uff0c\u8fd15\u65e5\u6709\u6f38\u9032\u56db\u80a2\u7121\u529b\u3001\u9ebb\u6728\uff0c\u4e26\u4f34\u96a8\u8d70\u52d5\u6703\u5598\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u8655\u3002\u8840\u58d3140/90 mmHg\u3001\u547c\u5438\u6bcf\u5206\u941816\u6b21\u3001\u5fc3\u8df3\u6bcf\u5206\u941890\u6b21\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u4e0a\u80a2\u808c\u529b3-4\u3001\u4e0b\u80a2\u808c\u529b4\u5206\u3001\u56db\u80a2\u7121\u808c\u8171\u53cd\u5c04\uff0c\u521d\u6b65\u8a3a\u65b7\u7591\u70ba\u6025\u6027\u795e\u7d93\u708e\u3002\u5f8c\u7e8c\u61c9\u5b89\u6392\u90a3\u4e9b\u8655\u7f6e\u8f03\u9069\u5b9c\uff1a(1). \u8170\u690e\u7a7f\u523a\u6aa2\u67e5 (2). \u8003\u616e\u9ad8\u5291\u91cf\u985e\u56fa\u9187\u6cbb\u7642 (3). \u8a55\u4f30\u5176\u541e\u56a5\u529f\u80fd\u53ca\u547c\u5438\u72c0\u6cc1 (4). \u62bd\u8840\u6aa2\u9a57\u4e4b\u524d\u7684\u611f\u67d3\u662f\u5426\u70ba\u5e38\u898b\u7684\u524d\u9a45\u611f\u67d3\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "108-1.\n12\u6b72\u7537\u7ae5\uff0c\u88ab\u8001\u5e2b\u767c\u73fe\u4e0a\u8ab2\u6703\u767c\u5446\uff0c\u8ab2\u696d\u8868\u73fe\u9000\u6b65\uff0c\u81f3\u91ab\u9662\u6aa2\u67e5\u8166\u96fb\u5716\u986f\u793a\u6709\u5927\u8166\u96d9\u5074\u5c0d\u7a313 Hz\u7684\u68d8\u6162\u8907\u5408\u6ce2\uff08spike-and-slow-wave discharges\uff09\uff0c\u95dc\u65bc\u6b64\u75be\u75c5\u7684\u767c\u4f5c\u6642\u8868\u73fe\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u5e38\u6703\u7728\u773c\nB. \u6709\u5480\u56bc\u52d5\u4f5c\nC. \u591a\u7121\u5026\u6020\u8868\u73fe\nD. \u96d9\u817f\u7121\u529b\u3001\u8dcc\u5750\nE. \u904e\u5ea6\u63db\u6c23\u6703\u8a98\u767c\n": "(D)", "108-2.\n75\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u5e73\u6642\u898f\u5247\u670d\u7528dabigatran(110)\uff0c\u7a81\u767c\u53f3\u5074\u7121\u529b\u8207\u8aaa\u8a71\u4e0d\u6e05\u695a\uff0c\u96a8\u5373\u88ab\u9001\u81f3\u67d0\u4e00\u793e\u5340\u91ab\u9662\u6025\u8a3a\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\u7684\u5206\u6578\u70ba7\u5206\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u986f\u793a\u7121\u8166\u5167\u51fa\u8840\uff0c\u81ea\u75c7\u72c0\u767c\u751f\u5df2\u7d93120\u5206\u9418\uff0c\u61c9\u9032\u884c\u4e0b\u5217\u4f55\u8655\u7f6e\u6700\u9069\u5b9c?\nA. \u7acb\u5373\u7d66\u4e88\u65b0\u9bae\u51b7\u51cd\u8840\u6f3f\uff08Fresh frozen plasma, FFP\uff09\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nB. \u7acb\u5373\u7d66\u4e88\u51dd\u8840?\u539f\u8907\u5408\u7269\u6fc3\u7e2e\u7269\uff08Prothrombin Complex Concentrate, PCC\uff09\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nC. \u7acb\u5373\u7d66\u4e88dabigatran\u53cd\u8f49\u5291idarucizumab\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nD. \u7acb\u5373\u8f49\u9662\u81f3\u53ef\u4ee5\u9032\u884c\u8840\u6813\u79fb\u9664\u7684\u91ab\u9662\nE. \u5148\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\uff0c\u518d\u8f49\u9662\u81f3\u53ef\u4ee5\u9032\u884c\u8840\u6813\u79fb\u9664\u7684\u91ab\u9662\n": "(C)", "108-3.\n\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6613\u6709\u81ea\u4e3b\u5468\u908a\u795e\u7d93\uff08autonomic neuropathy\uff09\u75c7\u72c0\u8868\u73fe?\nA. \u925b\u4e2d\u6bd2\u795e\u7d93\u75c5\u8b8a\uff08lead neuropathy\uff09\nB. \u7cd6\u5c3f\u75c5\u795e\u7d93\u75c5\u8b8a\uff08diabetic neuropathy\uff09\nC. \u6fb1\u7c89\u6a23\u795e\u7d93\u75c5\u8b8a\uff08amyloid neuropathy\uff09\nD. \u6025\u6027\u9593\u6b47\u6027\u7d2b\u8cea\u75c7\uff08acute intermittent porphyria\uff09\nE. \u8089\u6bd2\u687f\u83cc\u4e2d\u6bd2\uff08botulism\uff09\n": "(A)", "108-4.\n22\u6b72\u5973\u6027\uff0c\u8fd13\u500b\u6708\u6709\u6f38\u9032\u7684\u6613\u6012\u3001\u7cbe\u795e\u4e0d\u96c6\u4e2d\u3001\u8a18\u61b6\u529b\u4e0b\u964d\u3001\u7761\u7720\u969c\u7919\uff0c\u751a\u81f3\u6709\u5984\u60f3\u75c7\u72c0\uff0c\u81f3\u7cbe\u795e\u79d1\u5c31\u8a3a\uff0c\u7a81\u767c\u7672\u7647\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u521d\u6b65\u8a3a\u65b7\u70ba\u975e\u611f\u67d3\u6027\u8166\u708e\uff0c\u61c9\u512a\u5148\u8003\u616e\u5b89\u6392\u54ea\u4e9b\u6aa2\u67e5\uff1a(1)\u5fc3\u81df\u8d85\u97f3\u6ce2 (2)\u8179\u90e8\u9aa8\u76c6\u8154\u65b7\u5c64\u6383\u63cf (3)\u51dd\u8840\u76f8\u95dc\u8840\u6db2\u6aa2\u67e5 (4) \u514d\u75ab\u76f8\u95dc\u8840\u6db2\u6aa2\u67e5\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "108-5.\n\u4e0b\u5217\u54ea\u4e00\u90e8\u4f4d\u7684\u8166\u6897\u585e\u8f03\u4e0d\u5e38\u662f\u5fc3\u56e0\u6027\u8166\u6897\u585e\u767c\u751f\u4f4d\u7f6e?\nA. \u6795\u8449\uff08occipital lobe\uff09\nB. \u5c0f\u8166\u5916\u5074\uff08lateral cerebellum\uff09\nC. \u96d9\u6e2c\u8996\u4e18\uff08bilateral thalamus\uff09\nD. \u9802\u8449\u76ae\u8cea\u90e8\uff08parietal lobe cortex\uff09\nE. \u6a4b\u8166\u8fd1\u4e2d\u5074\uff08medial pons\uff09\n": "(E)", "108-6.\n50\u6b72\u7537\u6027\uff0c\u8fd1\u4e00\u500b\u6708\u5e7e\u4e4e\u6bcf\u65e5\u982d\u75db\uff0c\u75db\u5728\u9873\u8449\u3001\u773c\u5f8c\u90e8\u4f4d\uff0c\u6bcf\u6b21\u982d\u7684\u6642\u9593\u7d041-2\u5c0f\u6642\uff0c\u75db\u6642\u5019\u5408\u4f75\u6709\u9f3b\u585e\u3001\u6d41\u773c\u6dda\u75c7\u72c0\uff0c2\u5e74\u524d\u6709\u985e\u4f3c\u75c7\u72c0\u6301\u7e8c1-2\u500b\u6708\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u500b\u85e5\u7269\u4e0d\u6703\u9078\u64c7\u70ba\u9810\u9632\u982d\u75db\u767c\u4f5c\u85e5\u7269?\nA. Verapamil\nB. Gabapentin\nC. Indomethacin\nD. Topiramate\nE. Lithium\n": "(C)", "108-7.\n\u95dc\u65bc\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\uff08Korsakoff's syndrome\uff09\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u8207\u57fa\u5e95\u6838(basal ganglia)\u53d7\u5f71\u97ff\u76f8\u95dc\nB. \u6700\u4e3b\u8981\u75c7\u72c0\u70ba\u56b4\u91cd\u8a18\u61b6\u7f3a\u640d\nC. \u4e4b\u524d\u4e0d\u6703\u51fa\u73fe\u6709\u97cb\u5c3c\u514b\u6c0f\u8166\u75c5\u8b8a(Wernicke encephalopathy)\u75c7\u72c0\nD. \u7d93\u7dad\u4ed6\u547dB1\u6cbb\u7642\uff0c\u5927\u591a\u6578\u53ef\u4ee5\u660e\u986f\u6062\u5fa9\nE. MRI\u53ef\u898b\u9593\u8166(Diencephalon)\u840e\u7e2e\n": "(D)", "109-180.75\u6b72\u5973\u6027 \uff0c\u904e\u53bb\u6709\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\uff0c\u7a81\u767c\u8b1b\u8a71\u8a5e\u4e0d\u9054\u610f \uff0c\u9001\u81f3\u6025\u8a3a\u5f8c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5de6\u5074\u9802\u8449\u90e8\u6025\u6027\u6897\n\u585e\uff0c\u5247\u6703\u51fa\u73fe\u4e0b\u5217\u75c7\u72c0\u4f55\u8005\u9664\u5916 \uff1f   \nA.\u5de6\u53f3\u6df7\u6dc6\uff08right left disorientation\uff09\nB.\u624b\u6307\u8fa8\u8b58\u56f0\u96e3\uff08finger agnosia\uff09\nC.\u4e0d\u6703\u7a7f\u8863\uff08dressing apraxia\uff09\nD.\u8a08\u7b97\u56f0\u96e3\uff08acalculia\uff09   \nE.\u66f8\u5beb\u56f0\u96e3\uff08agraphia\uff09\n": "[C]", "109-181.65\u6b72\u7537\u6027 \uff0c2\u5e74\u524d\u958b\u59cb\u6709\u7126\u616e \u3001\u60c5\u7dd2\u4f4e\u843d \u3001\u7761\u7720\u5dee\u75c7\u72c0 \uff0c\u6f38\u6f38\u767c\u751f\u6b65\u614b\u4e0d\u7a69\u50f5\u786c \u3001\u8a18\u61b6\u8870\u9000 \uff0c\u5076\u6709\u8996\u5e7b\u89ba\n\u8207\u5984\u60f3\u75c7\u72c0 \uff0c\u6700\u53ef\u80fd\u662f\u4e0b\u5217\u4f55\u8a3a\u65b7 \uff1f   \nA.\u76ae\u8cea\u57fa\u5e95\u6838\u9000\u5316\uff08corticobasal ganglion degeneration\uff09\nB.\u591a\u7cfb\u7d71\u840e\u7e2e\uff08multiple system atrophy\uff09\nC.\u6f38\u9032\u6027\u4e0a\u6838\u9ebb\u75fa\uff08progressive supranuclear palsy\uff09\nD.\u8def\u6613\u9ad4\u5931\u667a\u75c7\uff08dementia with Lewy body\uff09\nE.\u984d\u9873\u8449\u5931\u667a\u75c7\uff08frontotemporal dementia\uff09\n": "[D]", "109-182.52\u6b72\u5973\u6027 \uff0c\u539f\u5373\u6709\u63a7\u5236\u4e0d\u5f88\u597d\u7684\u9ad8\u8840\u58d3 \uff0c\u67d0\u65e5\u8207\u4ed6\u4eba\u6fc0\u70c8\u722d\u5435\u5f8c \uff0c\u7a81\u767c\u5287\u70c8\u982d\u75db \uff0c\u5408\u4f75\u610f\u8b58\u6709\u4e9b\u6df7\u6c8c \uff0c\u7dca\n\u6025\u9001\u91ab\u5f8c\u78c1\u632f\u7167\u5f71\u986f\u793a\u8166\u90e8\u7684\u5169\u5074\u6795\u8449\u6709\u816b\u8139 \uff0c\u4f46\u7121\u6897\u585e\u6216\u51fa\u8840 \u3002\u95dc\u65bc\u6b64\u75be\u75c5 \uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u6b63\u78ba \uff1f   \nA.\u61c9\u512a\u5148\u8003\u616e\u8166\u8840\u7ba1\u708e\uff08cerebral vasculitis\uff09\nB.\u61c9\u8003\u616e\u5c0e\u7ba1\u662f\u8840\u7ba1\u651d\u5f71\uff08catheter angiography\uff09\nC.\u61c9\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nD.\u61c9\u7d66\u4e88\u975c\u8108\u9223\u96e2\u5b50\u963b\u65b7\u5291\nE.\u61c9\u7d66\u4e88\u6297\u7672\u7647\u85e5\u7269\n": "[D]", "109-183.50\u6b72\u7537\u6027 \uff0c\u6709\u9152\u766e\u8207\u66fe\u6709\u9152\u7cbe\u6212\u65b7\u75c7\u72c0 \uff0c\u56e0\u6025\u6027\u795e\u7d93\u75c7\u72c0 \uff0c\u5305\u62ec\u8907\u8996 \uff08diplopia\uff09\u3001 \u6b65\u5c65\u4e0d\n\u7a69\uff08ataxia\uff09\u3001 \u8a18\u61b6\u55aa\u5931 \uff08memory loss\uff09\u3001 \u6de1\u6f20 \uff08apathy\uff09\u3001 \u6df7\u6c8c \uff08confusion \uff09\u7b49\u5165\u9662\u6cbb\u7642 \uff0c\u521d\u6b65\u8a3a\u65b7\n\u70ba\u7dad\u751f\u7d20 B1\u7f3a\u4e4f\uff0c\u7d66\u4e88thiamine\u6cbb\u7642 \uff0c\u4e0b\u5217\u90a3\u4e00\u500b\u75c7\u72c0\u6062\u5fa9\u8f03\u5feb \uff1f   \nA.\u8907\u8996\nB.\u6b65\u5c65\u4e0d\u7a69\nC.\u8a18\u61b6\u55aa\u5931\nD.\u6de1\u6f20\nE.\u6df7\u6c8c\n": "[A]", "109-184.40\u6b72\u5973\u6027\u6709\u814e\u529f\u80fd\u4e0d\u5168\u53ca\u591a\u7a2e\u75be\u75c5 \uff0c\u6f38\u9032\u767c\u751f\u80a2\u9ad4\u8fd1\u7aef\u7121\u529b \uff0c\u4f46\u6c92\u6709\u75bc\u75db\u8207\u76ae\u819a\u8b8a\u8272 \uff0c\u521d\u6b65\u8a3a\u65b7\u70ba\u808c\u8089\u75c5\n\u8b8a\uff0c\u61f7\u7591\u8207\u4f7f\u7528\u7684\u85e5\u7269\u76f8\u95dc \uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u85e5\u7269\u9808\u512a\u5148\u8003\u616e \uff1f   \nA.Carvedilol\nB.Metformin\nC.Colchicine\nD.Furosemide\nE.Propafenone\n": "[C]", "109-185.25\u6b72\u7537\u6027 \uff0c\u8fd1\u5e7e\u5e74\u6bcf\u5e74\u5728\u51ac\u5b63\u6703\u6709\u53e2\u805a\u982d\u75db (cluster headache )\uff0c\u6bcf\u5929\u982d\u75db 1-2\u5c0f\u6642\uff0c\u9023\u7e8c5-6\u9031\uff0c\u5728\u6025\u6027\n\u5287\u70c8\u982d\u75db\u767c\u751f\u6642 \u3002\u90a3\u4e9b\u6cbb\u7642\u8f03\u80fd\u7de9\u89e3\u982d\u75db \uff1a(1) 100%\u6c27\u6c23\uff0c\u6bcf\u5206\u941810 -12\u5347\uff0c15-20\u5206\u9418\uff1b(2) \nSumatriptan\u53e3\u670d50 -100\u6beb\u514b (3) Verapamil\u53e3\u670d\u6bcf\u65e5160 -960\u6beb\u514b\uff1b(4) Indomethacin\u53e3\u670d25 -75\u6beb\u514b\uff0c\u6bcf\n\u65e53\u6b21\u3002   \nA.(1)+(3)\nB.(2)+(4)\nC.(1)+(4)\nD.(2)+(3)\nE.(1)+(2)+(3)+(4)   \n": "[A]", "109-186.\u95dc\u65bc\u5fc3\u623f\u986b\u52d5 \uff08atrial fibrillation \uff0cAF\uff09\uff0c \u4e0b\u5217\u4f55\u7a2e\u60c5\u5883\u8655\u7f6e\u8f03\u70ba\u6b63\u78ba \uff1a\n(1) 57\u6b72\u7537\u6027 \uff0c\u4e4b\u524d\u7121\u91cd\u5927\u75be\u75c5 \uff0c\u8fd13\u65e5\u6709\u5fc3\u8df3\u904e\u5feb\u4e14\u4e0d\u898f\u5247 \uff0c\u81f3\u6025\u8a3a\u6642\u986f\u793aAF \uff0c\u5fc3\u640f130\u6b21/\u5206\uff0c\u5148\u7d66\u53e3\n\u670d\u6297\u51dd\u5291 \uff0c\u66ab\u6642\u4e0d\u6574\u8108 \uff08cardioversion \uff09\n(2) 70\u6b72\u7537\u6027 \uff0c\u7a81\u767c\u6025\u6027\u8166\u6897\u585e \uff0c\u795e\u7d93\u75c7\u72c0\u8f15\u5fae \uff0c\u4e2d\u98a8\u5f8c\u767c\u73fe\u6709AF \uff0c\u5728\u4e2d\u98a8\u5f8c\u7b2c 3\u65e5\u958b\u59cb\u4f7f\u7528\u76f4\u63a5\u53e3\u670d\u6297\n\u51dd\u8840\u5291\uff08direct oral anticoagulant \uff0cDOAC\uff09\n(3) 80\u6b72\u5973\u6027 \uff0c\u5df2\u77e5\u6709AF\u4e26\u670d\u7528DOAC \uff0c\u56e0\u62d4\u7259\u505c\u7528\u4e86 2\u65e5\uff0c\u7a81\u767c\u77ed\u66ab\u8166\u7f3a\u8840 \uff0c\u7acb\u5373\u52a0\u56deDOAC\n(4) 85\u6b72\u5973\u6027 \uff0c\u5df2\u77e5\u6709AF\u4e26\u670d\u7528warfarin \uff0c\u7a81\u767c\u6025\u6027\u8166\u6897\u585e \uff0cNIHSS\u70ba8\u5206\uff0c\u8ddd\u4e2d\u98a8\u767c\u4f5c 2.5\u5c0f\n\u6642\uff0cINR=1.4\uff0c\u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\u6cbb\u7642   \nA.(1)+(3)\nB.(2)+(4)\nC.(1)+(4)\nD.(2)+(3)\nE.(1)+(2)+(3)+(4)\n": "[E]", "110-145.\u95dc\u65bc\u808c\u7121\u529b \uff08myasthenia gravis \uff09\u8207\u5176\u5b83\u7684\u795e\u7d93\u808c\u8089\u4ea4\u754c\u75be\u75c5 \uff08neuromuscular junction disorder\uff09\uff0c \u4e0b\n\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba \uff1a   \nA.\u808c\u7121\u529b\u572850\u6b72\u4e4b\u524d\u767c\u75c5\u5973\u6027\u8f03\u591a\uff0c50\u6b72\u4e4b\u5f8c\u5247\u7537\u5973\u6027\u5dee\u4e0d\u591a\u3002\nB.\u8089\u6bd2\u687f\u83cc\u4e2d\u6bd2\uff08botulism\uff09\u70ba\u7a81\u89f8\u524d\u75c5\u8b8a\u3002\nC.\u808c\u7121\u529b\u5371\u6a5f\uff08myasthenic crisis\uff09\u6642\u4f7f\u7528\u8840\u6f3f\u7f6e\u63db\u8853\u6216\u514d\u75ab\u7403\u86cb\u767d\u6cbb\u7642\u6548\u679c\u76f8\u8fd1\u3002\nD.MuSK\u578b\u7684\u808c\u7121\u529b\u4e00\u822c\u75c7\u72c0\u8f03\u8f15\uff0c\u9032\u5c55\u8f03\u7de9\u3002\nE.Lambert-Eaton\u808c\u7121\u529b\u75c7\u5019\u7fa4\u591a\u8207\u5c0f\u7d30\u80de\u80ba\u764c\u76f8\u95dc\u3002\n": "[D]", "110-146.70\u6b72\u7537\u6027 \uff0c\u56e0\u80f8\u8179\u4e3b\u52d5\u8108\u7624 \uff08thoracic-abdominal aortic aneurysm \uff09\u63a5\u53d7\u624b\u8853 \uff0c\u8853\u5f8c\u7a81\u767c\u96d9\u4e0b\u80a2\u7121\u529b \uff0c\u7406\n\u5b78\u8207\u795e\u7d93\u5b78\u6aa2\u67e5\u8f03\u4e0d\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u4f55\u8005 ?   \nA.\u4e0b\u80a2\u75db\u611f\u4e0b\u964d\u3002\nB.\u4e0b\u80a2\u6eab\u5ea6\u611f\u4e0b\u964d\u3002\nC.\u4e0b\u80a2\u9707\u52d5\u611f\u4e0b\u964d\u3002\nD.\u4f4e\u8840\u58d3\u3002\nE.\u5c3f\u5931\u7981\u3002\n": "[C]", "110-147.50\u6b72\u5973\u6027 \uff0c\u56e0\u8166\u52d5\u8108\u7624\u7834\u88c2\u81f4\u8718\u86db\u819c\u4e0b\u8154\u51fa\u8840\u5165\u9662 \uff0c\u63a5\u53d7\u593e\u52d5\u8108\u7624\u624b\u8853 \uff0c\u8853\u5f8c\u7b2c\u4e09\u65e5\u767c\u73fe\u8840\u9209\u504f\u4f4e \uff08124 \nmmol/L\uff09\uff0c \u795e\u7d93\u5b78\u5c1a\u7a69\u5b9a \uff0c\u6aa2\u67e5\u7d50\u679c\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba ?   \nA.24\u5c0f\u6642\u5c3f\u4e2d\u7684\u9209\u542b\u91cf\u589e\u52a0\u3002\nB.\u5c3f\u6db2\u6ef2\u900f\u58d3\uff08urine osmolarity\uff09\u589e\u52a0\u3002\nC.\u9ad4\u5167\u5448\u73fe\u4f4e\u5bb9\u7a4d\uff08hypovolemic\uff09\u3002\nD.\u7d66\u4e88\u7b49\u5f35\u6c2f\u5316\u9209\u6eb6\u6db2\u6ef4\u6ce8\u3002\nE.\u7d66\u4e88\u7518\u9732\u9187\uff08Mannitol\uff09\u6ef4\u6ce8\u3002\n": "[E]", "110-148.75\u6b72\u5973\u6027 \uff0c\u56e0\u6557\u8840\u6027\u4f11\u514b\u5165\u4f4f\u52a0\u8b77\u75c5\u623f \uff0c\u7d93\u6cbb\u7642\u5f8c\u610f\u8b58\u6062\u5fa9 \uff0c\u4f46\u4ecd\u70ba\u547c\u5438\u5668\u4f9d\u8cf4 \uff0c\u5169\u9031\u5f8c\u767c\u73fe\u56db\u80a2\u808c\u529b\u660e\n\u986f\u4e0b\u964d\u5408\u4f75\u808c\u8089\u840e\u7e2e \uff0c\u5247\u6b64\u75c5\u4eba\u7684\u6aa2\u67e5\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba ?   \nA.\u56db\u80a2\u808c\u8171\u53cd\u5c04\u4e0b\u964d\u3002\nB.\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\u986f\u793a\u50b3\u5c0e\u901f\u5ea6\u660e\u986f\u964d\u4f4e\u3002\nC.\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\u986f\u793a\u52d5\u4f5c\u96fb\u4f4d\uff08action potential\uff09\u660e\u986f\u4e0b\u964d\u3002   \nD.\u985e\u56fa\u9187\u6cbb\u7642\u5e6b\u52a9\u4e0d\u5927\u3002\nE.\u808c\u529b\u6062\u5fa9\u81f3\u5c11\u97003\u81f36\u500b\u6708\u6642\u9593\u3002\n": "[B]", "110-149.\u95dc\u65bc\u8166\u975c\u8108\u6813\u585e \uff08cerebral venous thrombosis \uff0cCVT\uff09\uff0c \u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba \uff1a\n(1) CVT\u53ea\u4ee5\u55ae\u4e00\u76ae\u8cea\u975c\u8108 \uff08cortical vein \uff09\u6813\u585e\u8868\u73fe\u8f03\u70ba\u5c11\u898b\n(2) \u4ee5\u5931\u8a9e\u8868\u73fe\u4e3b\u8981\u70baTrolard\u76ae\u8cea\u975c\u8108\u6813\u585e\n(3) COVID-19\u611f\u67d3\u4f75\u767cCVT \uff0c\u53ef\u80fd\u8207\u8a98\u767c\u6297\u8840\u5c0f\u677f\u56e0\u5b50 -4\uff08anti-platelet factor 4\uff09\u6297\u9ad4\u76f8\u95dc\n(4) \u8fc4\u4eca\u7814\u7a76 \uff0c\u975e\u7dad\u4ed6\u547d K\u53e3\u670d\u6297\u51dd\u5291\u4e26\u672a\u512a\u65bc\u7dad\u4ed6\u547d K\u53e3\u670d\u6297\u51dd\u5291\u5c0d\u65bcCVT\u518d\u767c\u751f\u7684\u9810\u9632   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "110-150.\u95dc\u65bc\u5f8c\u8166\u53ef\u9006\u6027\u8166\u75c5\u8b8a\u75c7\u5019\u7fa4 \uff08posterior reversible encephalopathy syndrome \uff0cPRES\uff09\uff0c \u4e0b\u5217\u6558\u8ff0\u4f55\n\u8005\u8f03\u6b63\u78ba \uff1a\n(1) \u8166\u90e8\u78c1\u632f\u9020\u5f71\u986f\u793aFLAIR\u5f71\u50cf\u6709\u9ad8\u5f37\u5ea6\u986f\u5f71 \uff0c\u8868\u793a\u8840\u7ba1\u6e90\u6027\u8166\u6c34\u816b \uff08vasogenic edema \uff09\u5b58\u5728\n(2) \u61c9\u8003\u616e\u7d66\u4e88\u975c\u8108\u8f38\u6ce8nicardipine \u3001labetalol\u3001hydralazine \u7b49\n(3) \u82e5\u8d77\u521d\u6536\u7e2e\u58d3\u70ba200 mmHg \uff0c\u61c9\u5feb\u901f\u65bc 1\u5c0f\u6642\u5167\u5c07\u6536\u7e2e\u58d3\u964d\u81f3140 mmHg\u4ee5\u4e0b\n(4) \u82e5\u70ba\u5b50\u7672\u75c7 \uff08eclampsia\uff09\uff0c \u61c9\u512a\u5148\u4f7f\u7528\u975c\u8108\u8f38\u6ce8magnesium sulphate   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "111-145.62\u6b72\u5973\u6027 \uff0c\u7121\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u53f2 \uff0c\u767c\u751f\u5de6\u5074\u984d\u8449\u90e8\u51fa\u8840\u81f4\u5931\u8a9e \uff0c4\u500b\u6708\u5f8c\u518d\u767c\u751f\u53f3\u5074\u9802\u8449\u90e8\u51fa\u8840 \uff0c\u95dc\u65bc\u6b64\n\u75be\u75c5\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba \uff1a   \nA.\u5177\u6709apolipoprotein E \u025b2 \u6216\u025b3\u8f03\u6613\u767c\u751f\u6b64\u75be\u75c5\u3002\nB.\u8166\u5e79\u4e5f\u662f\u597d\u767c\u751f\u51fa\u8840\u8655\u3002\nC.\u7537\u6027\u8f03\u5973\u6027\u5e38\u898b\u3002\nD.50-70\u6b72\u662f\u4e3b\u8981\u767c\u75c5\u5e74\u9f61\u5c64\u3002\nE.\u591a\u5408\u4f75\u76ae\u8cea\u90e8\u7684\u5fae\u5c0f\u51fa\u8840\u3002\n": "[E]", "111-146.\u6bd4\u8f03\u808c\u7121\u529b \uff08myasthenia gravis, MG \uff09\u8207\u85cd\u4f2f\uff0d\u4f0a\u9813\u808c\u7121\u529b\u75c7\u5019\u7fa4 \uff08Lambert-Eaton myasthenic \nsyndrome, LEMS\uff09\uff0c \u4e0b\u5217\u7684\u81e8\u5e8a\u8868\u73fe\u4f55\u8005\u8f03\u4e0d\u5e38\u767c\u751f\u65bcLEMS ?   \nA.\u8ec0\u5e79\u53ca\u8fd1\u7aef\u808c\u8089\u7684\u7121\u529b\u3002\nB.\u81ea\u5f8b\u795e\u7d93\u5931\u8abf\u7684\u75c7\u72c0\uff0c\u5982\u53e3\u4e7e\u3001\u4fbf\u79d8\u3001\u5c0f\u4fbf\u56f0\u96e3\u53ca\u6027\u7121\u80fd\u3002\nC.\u5408\u4f75\u5c0f\u7d30\u80de\u80ba\u764c\u767c\u751f\u3002\nD.\u96fb\u5b78\u6aa2\u67e5\u4ee5\u9ad8\u983b\u523a\u6fc0\uff08\u6bcf\u79d220-50\u6b21\uff09\uff0c\u904b\u52d5\u96fb\u4f4d\u7684\u632f\u5e45\u660e\u986f\u6e1b\u5c11\u3002\nE.P/Q\u578b\u614b\u7684\u9223\u96e2\u5b50\u901a\u9053\u6297\u9ad4\u3002\n": "[D]", "111-147.\u95dc\u65bc\u9752\u5c11\u5e74\u808c\u9663\u6523\u6027\u7672\u7647\uff08juvenile myoclonic epilepsy\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba?       \nA.\u5e38\u4ee5\u77ed\u66ab\u3001\u96d9\u5074\u5c0d\u7a31\u3001\u540c\u6b65\u3001\u7121\u7bc0\u5f8b\u7684\u808c\u8089\u6536\u7e2e\u8868\u73fe\u3002\nB.\u5e38\u767c\u751f\u65bc\u6e05\u6668\u525b\u8d77\u5e8a\u6642\u3002\nC.\u591a\u6703\u6709\u77ed\u66ab\u610f\u8b58\u55aa\u5931\u3002\nD.\u5e38\u6709\u7672\u7647\u5bb6\u65cf\u53f2\u3002\nE.\u795e\u7d93\u7cfb\u7d71\u767c\u80b2\u5927\u591a\u6b63\u5e38\u3002\n": "[C]", "111-148.\u95dc\u65bc\u97cb\u5c3c\u514b-\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\uff08Wernicke-Korsakoff syndrome\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba?    \nA.\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\u591a\u767c\u751f\u5728\u97cb\u5c3c\u514b\u8166\u75c7\uff08Wernicke encephalopathy\uff09\u4e4b\u5f8c\u3002\nB.\u80a2\u9ad4\u5931\u8abf\uff08limb ataxia\uff09\u8f03\u8ec0\u5e79\u5931\u8abf\uff08truncal ataxia\uff09\u5e38\u898b\u3002\nC.\u773c\u808c\u9ebb\u75f9\uff08ophthalmoplegia\uff09\u5e38\u4ee5\u8907\u8996\uff08diplopia\uff09\u3001\u773c\u77bc\u4e0b\u5782\uff08ptosis\uff09\u8868\u73fe\u3002\nD.\u6b65\u614b\u4e0d\u7a69\u8207\u5408\u4f75\u591a\u767c\u6027\u795e\u7d93\u75c5\u8b8a\u3001\u5c0f\u8166\u75c5\u8b8a\u76f8\u95dc\u3002\nE.\u6cbb\u7642\u5f8c\u773c\u808c\u9ebb\u75f9\u8f03\u6b65\u614b\u4e0d\u7a69\u6062\u5fa9\u5feb\u3002\n": "[C]", "111-149.\u95dc\u65bc\u53e3\u670d\u6297\u51dd\u8840\u5291\u76f8\u95dc\u4e4b\u8166\u5167\u51fa\u8840 \uff08anticoagulant related intracerebral hemorrhage \uff09\u7684\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\n\u4f55\u8005\u8f03\u6b63\u78ba \uff1a\n(1) \u7dad\u4ed6\u547dK\u6297\u51dd\u8840\u5291 \uff08vitamin K antagonists\uff09\uff1a \u5148\u7d66\u65b0\u9bae\u51b7\u51cd\u8840\u6f3f \uff08fresh frozen plasma, FFP\uff09\uff0c \u518d\u7d66\n\u51dd\u8840\u9176\u8907\u5408\u6fc3\u7e2e\u7269 \uff08prothrombin complex concentrate, PCC \uff09\u8207vitamin K\n(2) Dabigatran \uff1a\u7acb\u5373\u7d66\u4e88\u55ae\u682a\u6297\u9ad4idarucizumab\n(3) Factor Xa inhibitors \uff1a\u82e5\u7121andexanet alpha \uff0c\u5247\u7d66\u4e88PCC \n(4) Factor Xa inhibitors \uff1a\u82e5\u7121andexanet alpha \uff0c\u4e5f\u53ef\u8003\u616e\u814e\u81df\u66ff\u4ee3\u7642\u6cd5 \uff08renal replacement therapy \uff09   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[D]", "111-150.\u660f\u53a5\u75c5\u4eba\u9032\u884c\u81ea\u4e3b\u795e\u7d93\u529f\u80fd\u6e2c\u8a66 \uff0c\u4e0b\u5217\u4f55\u8005\u4e3b\u8981\u70ba\u526f\u4ea4\u611f\u795e\u7d93\u529f\u80fd\u6e2c\u8a66 \uff1a\n(1) \u6bcf\u5206\u94186\u6b21\u6df1\u547c\u5438\u6642\u7684\u5fc3\u5f8b\u8b8a\u7570 \uff08heart rate variation with deep breathing \uff09\n(2) \u6d41\u6c57\u6e2c\u8a66 \uff08quantitative sudomotor axon reflex test, QSART \uff09\n(3) \u9589\u6c23\u7528\u529b--\u4f10\u6c0f\u64cd\u4f5c\u6642\u6700\u5feb\u5fc3\u8df3\u6bd4\u6700\u6162\u5fc3\u8df3 \uff08Valsalva ratio \uff09\n(4) \u50be\u659c\u5e8a\u6e2c\u8a66 \uff08head-up tilt table test \uff09   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[A]"}